Grants per year
Personal profile
Research Interests
Colon cancer, Gastric cancer, Pancreas cancer, Rectal cancer
Certifications and Licenses
Internal Medicine | |
Medical Oncology |
Training Experience
1979 | Residency, Univ. of Wisconsin Hospital |
1984 | Fellowship, Univ. of Wisconsin Hospital |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Medicine, MD, SUNY Buffalo
… → 1976
Research interests keywords
- Anal Cancer
- Colon/Rectal Cancer
- Esophageal Cancer
- GI Stromal Tumors
- Gastrointestinal Malignancies
- Liver Cancer
- Neuroendocrine Tumors
- Pancreatic Cancer
- Stomach Cancer
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Prot #PRISM-1: A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma
Benson III, A. B. (PD/PI)
ICON Clinical Research, LLC, Arcus Biosciences, Inc
1/25/25 → 1/24/28
Project: Research project
-
Prot #M24-064: AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing ABBV-400 Monotherapy to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with c-Met Over-Expressed Refractory Metastatic Colorectal Ca
Benson III, A. B. (PD/PI)
11/6/24 → 11/6/27
Project: Research project
-
Prot #CRDF-004: A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer
Benson III, A. B. (PD/PI)
Pfizer Inc., Cardiff Oncology, Inc.
10/1/24 → 10/1/25
Project: Research project
-
Prot #219606: A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy versus Standard of Care in Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Benson III, A. B. (PD/PI)
PPD Investigator Services, LLC, GlaxoSmithKline LLC
6/18/24 → 6/18/27
Project: Research project
-
Prot #1438-0007: DAREON™-7: A Phase I, Open-Label, Dose Escalation and Expansion Trial to Investigate Safety and Tolerability of BI 764532 Intravenous Infusions in Combination with Standard of Care (Platinum and Etoposide) in First-Line Treatment of Patie
Benson III, A. B. (PD/PI)
Boehringer Ingelheim Pharmaceuticals, Inc.
3/16/24 → 3/16/27
Project: Research project
-
Delta Radiomics and Tumor Size: A New Predictive Radiomics Model for Chemotherapy Response in Liver Metastases from Breast and Colorectal Cancer
Gennaro, N., Soliman, M., Borhani, A. A., Kelahan, L., Savas, H., Avery, R. J., Subedi, K., Trabzonlu, T. A., Krumpelman, C., Yaghmai, V., Chae, Y. K., Lorch, J., Mahalingam, D., Mulcahy, M., Benson III, A. B., Bagci, U. & Velichko, Y. S., Mar 2025, In: Tomography. 11, 3, 20.Research output: Contribution to journal › Article › peer-review
Open Access -
Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline
Morris, V. K., Kennedy, E. B., Amin, M. A., Aranha, O., Benson, A. B., Dorth, J. A., Horowitz, D. P., Kennecke, H. F., Kim, S., Kreppel, L., Mettu, N. B., Rajdev, L., Riechelmann, R., Sio, T. T. & Eng, C., Feb 10 2025, In: Journal of Clinical Oncology. 43, 5, p. 605-615 11 p.Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
Yttrium-90 Radiation Segmentectomy for Treatment of Neuroendocrine Liver Metastases
Gordon, A. C., Savoor, R., Kircher, S. M., Kalyan, A., Benson, A. B., Hohlastos, E., Desai, K. R., Sato, K., Salem, R. & Lewandowski, R. J., Feb 2025, In: Journal of vascular and interventional radiology : JVIR. 36, 2, p. 293-300 8 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Stearns, V., Jegede, O. A., Chang, V. T. S., Skaar, T. C., Berenberg, J. L., Nand, R., Shafqat, A., Jacobs, N. L., Luginbuhl, W., Gilman, P., Benson, A. B., Goodman, J. R., Buchschacher, G. L., Henry, N. L., Loprinzi, C. L., Flynn, P. J., Mitchell, E. P., Fisch, M. J., Sparano, J. A. & Wagner, L. I., Jul 1 2024, In: Clinical Cancer Research. 30, 13, p. 2709-2718 10 p.Research output: Contribution to journal › Article › peer-review
3 Scopus citations -
An update on pharmacotherapies for colorectal cancer: 2023 and beyond
Zhu, M. & Benson, A. B., 2024, In: Expert Opinion on Pharmacotherapy. 25, 1, p. 91-99 9 p.Research output: Contribution to journal › Review article › peer-review
5 Scopus citations
Datasets
-
Supplementary Material for: Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma with Tumor Mutation Profiling
Kelley, R. K. (Contributor), Joseph, N. M. (Contributor), Nimeiri, H. S. (Contributor), Hwang, J. (Contributor), Kulik, L. M. (Contributor), Ngo, Z. (Contributor), Behr, S. C. (Contributor), Onodera, C. (Contributor), Zhang, K. (Contributor), Bocobo, A. G. (Contributor), Benson, A. B. (Contributor), Venook, A. P. (Contributor) & Gordan, J. D. (Contributor), Karger Publishers, 2021
DOI: 10.6084/m9.figshare.16573370.v1, https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Phase_II_Trial_of_the_Combination_of_Temsirolimus_and_Sorafenib_in_Advanced_Hepatocellular_Carcinoma_with_Tumor_Mutation_Profiling/16573370/1
Dataset